Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs

被引:57
作者
Boger, E. [1 ,2 ]
Evans, N. [2 ]
Chappell, M. [2 ]
Lundqvist, A. [1 ]
Ewing, P. [1 ]
Wigenborg, A. [1 ]
Friden, M. [1 ,3 ]
机构
[1] AstraZeneca R&D, Dept Resp Inflammat & Autoimmun Innovat Med, Molndal, Sweden
[2] Univ Warwick, Sch Engn, Coventry, W Midlands, England
[3] Uppsala Univ, Dept Pharmaceut Biosci, Translat PKPD, Uppsala, Sweden
基金
英国工程与自然科学研究理事会;
关键词
D O I
10.1002/psp4.12074
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pulmonary drug disposition after inhalation is complex involving mechanisms, such as regional drug deposition, dissolution, and mucociliary clearance. This study aimed to develop a systems pharmacology approach to mechanistically describe lung disposition in rats and thereby provide an integrated understanding of the system. When drug-and formulation-specific properties for the poorly soluble drug fluticasone propionate were fed into the model, it proved predictive of the pharmacokinetics and receptor occupancy after intravenous administration and nose-only inhalation. As the model clearly distinguishes among drug-specific, formulation-specific, and system-specific properties, it was possible to identify key determinants of pulmonary selectivity of receptor occupancy of inhaled drugs: slow particle dissolution and slow drug-receptor dissociation. Hence, it enables assessment of factors for lung targeting, including molecular properties, formulation, as well as the physiology of the animal species, thereby providing a general framework for rational drug design and facilitated translation of lung targeting from animal to man.
引用
收藏
页码:201 / 210
页数:10
相关论文
共 43 条
[1]  
Agu RU, 2001, RESP RES, V2, P198
[2]   A MULTIPLE-PATH MODEL OF PARTICLE DEPOSITION IN THE RAT LUNG [J].
ANJILVEL, S ;
ASGHARIAN, B .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1995, 28 (01) :41-50
[3]  
Arundel P. A., 1997, MULTICOMPARTMENTAL M
[4]   Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product [J].
Backman, P. ;
Adelmann, H. ;
Petersson, G. ;
Jones, C. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) :509-520
[5]  
Backstrom E., 2015, J PHARM SCI
[6]   A Novel In Vivo Receptor Occupancy Methodology for the Glucocorticoid Receptor: Toward An Improved Understanding of Lung Pharmacokinetic/Pharmacodynamic Relationships [J].
Boger, Elin ;
Ewing, Par ;
Eriksson, Ulf G. ;
Fihn, Britt-Marie ;
Chappell, Michael ;
Evans, Neil ;
Friden, Markus .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 353 (02) :279-287
[7]   Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs [J].
Borghardt, Jens Markus ;
Weber, Benjamin ;
Staab, Alexander ;
Kloft, Charlotte .
AAPS JOURNAL, 2015, 17 (04) :853-870
[8]   Physiological parameter values for physiologically based pharmacokinetic models [J].
Brown, RP ;
Delp, MD ;
Lindstedt, SL ;
Rhomberg, LR ;
Beliles, RP .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1997, 13 (04) :407-484
[9]  
Brunner E., 1904, H-S Z PHYSIOL CHEM, V47, P56
[10]   A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry [J].
Campbell, Jerry L. ;
Andersen, Melvin E. ;
Clewell, Harvey J. .
INHALATION TOXICOLOGY, 2014, 26 (06) :333-344